Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of ulinastatin in preparation of medicament for treating systemic lupus erythematosus and medicinal composition of ulinastatin

A technology for ulinastatin and lupus erythematosus, which is used in the drug for the treatment of systemic lupus erythematosus. unbearable problems

Active Publication Date: 2013-09-25
GUANGDONG TECHPOOL BIO-PHARMA CO LTD
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The standard treatment of SLE is the use of glucocorticoids and immunosuppressants such as cyclophosphamide, etc., which can be used to relieve symptoms, but they cannot cure SLE. Long-term or high-dose hormone therapy is often accompanied by serious side effects such as infection, gonadal suppression, and Tumors, etc., and cannot significantly affect the progression of the disease or turn into life-threatening renal complications (lupus nephritis)
New immunosuppressants, biological agents, plasma exchange, autologous stem cell transplantation and other treatment methods not only need long-term clinical verification of efficacy, but also the cost of treatment can range from tens of thousands of yuan per year to hundreds of thousands of yuan per year, which is unbearable for many patients , so there is a need to technically develop new methods of treating SLE

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of ulinastatin in preparation of medicament for treating systemic lupus erythematosus and medicinal composition of ulinastatin
  • Use of ulinastatin in preparation of medicament for treating systemic lupus erythematosus and medicinal composition of ulinastatin
  • Use of ulinastatin in preparation of medicament for treating systemic lupus erythematosus and medicinal composition of ulinastatin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Embodiment 1 prepares ulinastatin dry powder injection

[0013] Take 100 million units of filtered sterilized ulinastatin aqueous solution, add 20 grams of mannitol to dissolve, adjust the pH to neutral, add water for injection to 2000 ml, add sodium chloride to adjust isotonicity, filter aseptically, and pack in 1000 pieces In a vial, freeze-dried under sterile conditions, to obtain.

Embodiment 2

[0014] Embodiment 2 prepares ulinastatin injection

[0015] Take 100 million units of ulinastatin aqueous solution sterilized by filtration, adjust the pH to neutral, add water for injection to 2000 ml, add sodium chloride to adjust isotonicity, filter aseptically, pack in 1000 vials, and obtain.

Embodiment 3

[0016] The therapeutic effect of embodiment 3 ulinastatin on lupus erythematosus mice

[0017] Part 1: Selection and establishment of lupus-like mouse model of chronic graft-versus-host disease

[0018] The mouse model of chronic graft-versus-host disease lupus-like (cGVHD) is a good example of lupus murine nephritis. Several autoantibodies can appear in the model body, including anti-dsDNA, ssDNA, and histone antibodies, and fatal lupus-like nephritis can also appear. The experimental animals are 6-8 weeks old female (C57BL / 6J×DBA / 2) F1 hybrid mice and 6-8 weeks old female DBA / 2 mice, weighing (18-20) g, clean grade. Observation, testing, and evaluation of blood, urine, and basic status were carried out regularly before and after modeling. Under sterile conditions, the spleen, lymph nodes (mesentery, groin, and neck) and thymus of DBA / 2 mice were taken out, cut into pieces, ground, washed with PBS and sieved, and the cell suspension was sieved at a ratio of 1:1. Slowly add...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the use of ulinastatin in the preparation of a medicament for treating systemic lupus erythematosus. The medicament of the invention is derived from natural protein medicaments extracted from human urine, has a stable and reliable quality and fewer unwanted effects and overcomes the shortcomings of generating more side effects, influencing the living quality of a patient, even causing death of the patient and the like when the conventional medicaments such as glucocorticoid, yclophosphamide, azathioprine and cyclosporine A are used for treating the systemic lupus erythematosus. According to the comparative study on the treatment effect of lupous animal models, the treatment effect of the ulinastatin is the same as that of a hormone contrast group.

Description

technical field [0001] The present invention relates to the field of medicinal chemistry. Specifically, the present invention relates to a medicine for treating systemic lupus erythematosus, in particular to an application of ulinastatin as a medicine for treating systemic lupus erythematosus. Background technique [0002] Systemic lupus erythematosus (SLE) is an autoimmune disease that seriously endangers human health. The prevalence rate in my country is close to one in a thousand, and the total number of patients in the country is as high as 1 million. So far, there is no specific effective treatment at home and abroad. [0003] Systemic lupus erythematosus (SLE) is an autoimmune disease with complex and diverse clinical manifestations involving multiple systems and organs. The etiology is still not completely clear, it may be based on genetic factors, stimulated by environmental factors, triggers abnormal immune response, continuously produces a large number of pathoge...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/57A61P37/02A61P13/12
Inventor 傅和亮邹春芽吴蓉蓉华明娟陈颖
Owner GUANGDONG TECHPOOL BIO-PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com